Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany

@article{Kuhlmann2016ModelingTC,
  title={Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany},
  author={Alexander Kuhlmann and J. -M. Graf von der Schulenburg},
  journal={The European Journal of Health Economics},
  year={2016},
  volume={18},
  pages={273-292}
}
In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the cost-effectiveness of universal infant (<2 years old) vaccination with a 13-valent pneumococcal conjugate vaccine (PCV13) in comparison with a 10-valent pneumococcal conjugate vaccine (PCV10) for the prevention of pneumococcal disease in Germany. A population-based Markov model was developed to estimate the impact of PCV13 and PCV10 on invasive… CONTINUE READING